Warning Letter — Shimoga Chemicals
The FDA issued a Warning Letter to Shimoga Chemicals following an inspection by the Center for Drug Evaluation and Research (CDER). The letter identifies regulatory violations at the firm’s manufacturing facility.
Shimoga Chemicals, pharmaceutical manufacturers utilizing their chemical or drug products, and quality assurance personnel responsible for supplier oversight and CGMP compliance.
A Warning Letter from CDER indicates a formal assessment of significant regulatory non-compliance, typically involving deviations from CGMP. This suggests potential risks to the quality and consistency of the firm's output, which may necessitate increased scrutiny of materials sourced from this entity and could impact their ability to export products to the U.S. market.
Quality units should conduct immediate audits of active pharmaceutical ingredient (API) manufacturing sites to ensure adherence to Current Good Manufacturing Practice (CGMP). Regulatory teams must oversee responses to Warning Letters to prevent potential escalation to import alerts or seizure of goods.
FDA Warning Letter issued to: Shimoga Chemicals. 07/13/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shimoga-chemicals-727904-07132026
Open in openFDA / FDA.gov